

World Pain Relieving Drug Market 2013-2023

<https://marketpublishers.com/r/W5C0C508213EN.html>

Date: July 2013

Pages: 257

Price: US\$ 2,635.00 (Single User License)

ID: W5C0C508213EN

Abstracts

New study reveals sales potential of this large, expanding market

See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You see why the pain relievers industry and market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 84 tables, 79 charts and three research interviews.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of five world-level submarkets to 2023:

Narcotics

Non-narcotics

Neuropathic pain relievers

Treatments for migraines

Treatments for arthritis.

Also, you see how 29 leading drugs - including Oxycontin ER, Panadol, Lyrica and Zomig - can perform to 2023. Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. There, you find revenue forecasts and other data.

The work also breaks the overall world market into leading national markets.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

You discover revenue forecasts to 2023 for twelve national markets:

US

Japan

Germany, France, UK, Italy and Spain (EU5 nations)

India

China

Brazil

Russia

Turkey

This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D pipeline for painkillers? You see developmental trends there:

Narcotic drugs

Non-narcotic products

Neuropathic treatments

Anti-migraine agents

Arthritic pain relievers.

Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the pain treatment sector

Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:

Better treatment of acute and chronic pain worldwide, including cancer pain

Anticonvulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics

Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors

Disease modifying anti-rheumatic drugs (DMARDs)

Biologics (e.g. monoclonal antibodies, MAbs) for rheumatoid arthritis (RA)

Reimbursement, regulations, patent expiries, generic competition and OTC switching.

You see discussions of technological, commercial and economic matters, with

emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues there from 2013 to 2023. The R&D pipeline is strong.

Overall world revenue for that market area will reach \$68.0bn in 2013, our report forecasts. Ageing populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.

Eight ways World Pain Relieving Drug Market 2013-2023 benefits you

In particular, then, our study gives you the following knowledge on painkilling drugs:

- Forecasted revenues to 2023 for the overall world market and submarkets

- Potential revenues of 29 leading products to 2023

- Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil, Russia and Turkey

- Assessment of companies - discussions of activities and outlooks

- Review of R&D pipelines by treatment area - progress and trends

- Opinions on the sector, including our research interviews with leaders in industry

- Investigation of competition and opportunities influencing sales

- Discussion of what stimulates and restrains the industry and market.

That work gives independent analyses from our primary and secondary research. You receive information found only in our report.

With our study, you find business intelligence to help you understand the future of that industry and market.

Ordering now lets you discover prospects for drugs treating pain

Visiongain's study is for everybody needing commercial analyses for the treatment of pain. You find data, trends and predictions there. Please order that report now.

Contents

1. EXECUTIVE SUMMARY

- 1.1 The Pain Relieving Drug Market: Overview
- 1.2 Aims, Scope and Format of the Report
- 1.3 Research and Analysis Methods

2. INTRODUCTION TO THE PAIN RELIEVING DRUG MARKET

- 2.1 What is Pain?
 - 2.1.1 Historical Aspects of Pain
- 2.2 Pain Pathways and the Origin of Pain
 - 2.2.1 WHO Pain Ladder
- 2.3 Classification and Types of Pain
 - 2.3.1 Acute Pain
 - 2.3.2 Chronic Pain
 - 2.3.3 Psychosocial Effects of Chronic Pain
 - 2.3.4 Chronic Cancer Pain
 - 2.3.5 Breakthrough Cancer Pain
- 2.4 Neuropathic Pain
 - 2.4.1 Distinguishing Neuropathic Pain
- 2.5 Neurochemistry of Pain
 - 2.5.1 Prostaglandins
 - 2.5.2 Opioids
- 2.6 Treatment
 - 2.6.1 Opioids in the Treatment of Pain
- 2.7 OTC Pain Relievers

3. THE WORLD PAIN RELIEVING DRUG MARKET, 2013-2023

- 3.1 The World Pain Relieving Drug Market: Analysis and Forecast, 2013-2023
- 3.2 Submarket Categories of the World Pain Drug Market
 - 3.2.1 Anti-Arthritic Drug Sales Will Continue to Dominate
 - 3.2.2 Neuropathic Pain Market Will Grow
- 3.3 Success in the World Pain Treatment Market Has Been Challenging
- 3.4 The Pain Relieving Drug Market Will Expand

4. NARCOTIC PAIN RELIEVING DRUGS: WORLD MARKET ANALYSIS AND

FORECAST, 2013-2023

- 4.1 Oxycontin ER (Purdue Pharma): Market Analysis and Forecast, 2013-2023
 - 4.1.1 Launch of Tamper Resistant Oxycontin ER
 - 4.1.2 Patent and Legal Battles of Oxycontin ER
 - 4.1.3 Oxycontin ER Sales Forecast, 2013-2023
- 4.2 Opana ER (Endo Pharmaceuticals): Market Analysis and Forecast, 2013-2023
 - 4.2.1 Development of Tamper Resistant Opana ER
 - 4.2.2 Opana ER Sales Forecast, 2013-2023
- 4.3 Duragesic (Johnson & Johnson): Market Analysis and Forecast, 2013-2023
 - 4.3.1 Duragesic Sales Forecast, 2013-2023
- 4.4 Ultram (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2013-2023
- 4.5 Zaldiar/Ultracet (Gr??nenthal): Market Analysis and Forecast, 2013-2023
- 4.6 World Market Forecast for Other Narcotic Drugs, 2013-2023

5. NON-NARCOTIC PAIN RELIEVING DRUGS: WORLD MARKET ANALYSIS AND FORECAST, 2013-2023

- 5.1 Advil (Pfizer): Market Analysis and Forecast, 2013-2023
 - 5.1.1 Development of Advil (Ibuprofen)
 - 5.1.2 Advil Sales Forecast, 2013-2023
- 5.2 Panadol (GSK): Market Analysis and Forecast, 2013-2023
 - 5.2.1 Panadol Sales Forecast, 2013-2023
- 5.3 Bayer Aspirin (Bayer): Market Analysis and Forecast, 2013-2023
 - 5.3.1 Development of Bayer Aspirin (Acetylsalicylic Acid)
 - 5.3.2 Bayer Aspirin Sales Forecast, 2013-2023
- 5.4 Efferalgan (Bristol-Myers Squibb): Market Analysis and Forecast, 2013-2023
- 5.5 Tylenol (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2013-2023
 - 5.5.1 Eroded Sales in 2012
 - 5.5.2 Tylenol Sales Forecast, 2013-2023
- 5.6 Other Non-Narcotic Pain Relieving Drugs: Market Analysis and Forecast, 2013-2023

6. NEUROPATHIC PAIN RELIEVING DRUGS: WORLD MARKET ANALYSIS AND FORECAST, 2013-2023

- 6.1 Treatment Options
- 6.2 Pharmacological Treatments

- 6.2.1 Anti-Convulsants
- 6.2.2 Analgesics
- 6.2.3 Local Anaesthetics
- 6.2.4 Anti-Depressants
- 6.2.5 Aldose Reductase Inhibitors
- 6.3 World Neuropathic Pain Relieving Drug Sales Forecast, 2013-2023
- 6.4 Lyrica (Pfizer): Market Analysis and Forecast, 2013-2023
 - 6.4.1 Impact of Lyrica Patent Expiry
- 6.5 Cymbalta (Eli Lilly): Market Analysis and Forecast, 2013-2023
- 6.6 Lidoderm (Endo Pharmaceuticals): World Market Analysis and Forecast, 2013-2023
 - 6.6.1 Impact of Lidoderm Patent Expiry
- 6.7 Neurontin Market Forecast, 2013-2023
- 6.8 Nucynta Franchise (Gr??nenthal GmbH, Johnson & Johnson): Market Analysis and Forecast, 2013-2023
 - 6.8.1 Development of Nucynta ER (Tapentadol)
 - 6.8.2 Nucynta Franchise Sales Forecast, 2013-2023
 - 6.8.3 Nucynta Franchise Has High Potential
- 6.9 Qutenza (NeurogesX) and NGX-1998 Market Prospects
- 6.10 Kinedak (Ono Pharmaceuticals) Market Prospects
- 6.11 Development and Market Prospects of Horizant (Xenoport, GSK)
- 6.12 Will Gralise (Depomed) Become a Market Leader?
- 6.13 Future Treatment of Neuropathies
 - 6.13.1 Therapies That Can Target the Underlying Cause Are in Demand

7. ANTI-MIGRAINE DRUGS: WORLD MARKET ANALYSIS AND FORECAST, 2013-2023

- 7.1 How is Migraine Treated and Prevented?
 - 7.1.1 Migraine Treatment
 - 7.1.2 Migraine Prevention
- 7.2 World Anti-Migraine Drug Sales Forecast, 2013-2023
- 7.3 Maxalt (Merck & Co.): Market Analysis and Forecast, 2013-2023
- 7.4 Zomig (AstraZeneca): Market Analysis and Forecast, 2013-2023
- 7.5 Relpax (Pfizer): Market Analysis and Forecast, 2013-2023
- 7.6 Imitrex/Imigran (GSK): Market Analysis and Forecast, 2013-2023
- 7.7 Botox (Allergan): Market Analysis and Forecast, 2013-2023
 - 7.7.1 Botox Will Boost World Migraine Sales
- 7.8 Axert (Johnson & Johnson, Almirall): Market Analysis and Forecast, 2013-2023
- 7.9 Treximet (GSK, Pozen): Market Analysis and Forecast, 2013-2023

7.10 What Does the Future Hold for Migraine Therapy?

7.11 Unmet Needs in the Treatment of Migraine

8. ANTI-ARTHRITIC PAIN DRUGS: WORLD MARKET ANALYSIS AND FORECAST, 2013-2023

8.1 Arthritis

8.2 What Drugs are used to Treat Arthritis?

8.2.1 Pain Relieving Drugs and Analgesics

8.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

8.2.3 Corticosteroids

8.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)

8.2.5 Biologics

8.3 Biologics for Rheumatoid Arthritis Treatment

8.3.1 Side Effects of Biologics

8.4 World Anti-Arthritic Pain Drug Sales Forecast, 2013-2023

8.5 Humira (Abbott Laboratories): Market Analysis and Forecast, 2013-2023

8.5.1 Long-Term Prospects for Humira

8.6 Enbrel (Amgen, Pfizer, Takeda): Market Analysis and Forecast, 2013-2023

8.6.1 Amgen Continues to Benefit from Enbrel Sales

8.6.2 Enbrel Sales Will Show an Initial Increase

8.6.3 Study Eases Fears of TNF Blocker Cancer Risk

8.6.4 New Enbrel Delivery System

8.6.5 Sales of Enbrel will Eventually Decline

8.6.6 Enbrel Faces Competition from Several Other Biotech Drugs

8.7 Remicade (Johnson & Johnson): Market Analysis and Forecast, 2013-2023

8.7.1 Long Term Prospects for Remicade

8.8 Rituxan (MabThera-Roche; Biogen Idec): Market Analysis and Forecast, 2013-2023

8.8.1 Rituxan is a Leading Biosimilar Target

8.9 Celebrex (Pfizer): Market Analysis and Forecast, 2013-2023

8.9.1 Development of Celebrex

8.9.2 Celebrex Sales Forecast, 2013-2023

8.10 Voltaren (Endo, Novartis): Market Analysis and Forecast, 2013-2023

8.10.1 Voltaren Sales Forecast, 2013-2023

8.11 Arcoxia (Merck & Co.): Market Analysis and Forecast, 2013-2023

8.11.1 Development of Arcoxia

8.11.2 Arcoxia Sales Forecast, 2013-2023

8.12 Outlook for the Anti-Arthritic Pain Drug Market

9. LEADING NATIONAL MARKETS FOR PAIN RELIEVING DRUGS, 2013-2023

- 9.1 The Pain Relieving Drug Market: Regional Sales Breakdown
- 9.2 Pain Drug Revenues in Leading National Markets, 2013-2023
 - 9.2.1 The Pain Relieving Drug Market in the US, 2013-2023
 - 9.2.2 The Pain Relieving Drug Market in Japan, 2013-2023
 - 9.2.3 Top 5 EU Markets for Pain Relieving Drugs, 2013-2023
 - 9.2.4 The Pain Relieving Drug Market in Germany, 2013-2023
 - 9.2.5 The Pain Relieving Drug Market in France, 2013-2023
 - 9.2.6 The Pain Relieving Drug Market in the UK, 2013-2023
 - 9.2.7 The Pain Relieving Drug Market in Italy, 2013-2023
 - 9.2.8 The Pain Relieving Drug Market in Spain, 2013-2023
- 9.3 Emerging Economies Showing Strong Performance, 2013-2023
 - 9.3.1 The Pain Relieving Drug Market in China, 2013-2023
 - 9.3.2 The Pain Relieving Drug Market in Brazil, 2013-2023
 - 9.3.3 The Pain Relieving Drug Market in Russia, 2013-2023
 - 9.3.4 The Pain Relieving Drug Market in India, 2013-2023
 - 9.3.5 The Pain Relieving Drug Market in Turkey, 2013-2023
- 9.4 The Pain Relieving Drug Market in the Rest of the World, 2013-2023

10. THE R&D PIPELINE FOR THE TREATMENT OF PAIN, 2013

- 10.1 The R&D Pipeline for Pain Drugs is Large and Expanding
- 10.2 The Potential of the Pain Market Has Encouraged R&D
- 10.3 Innovation Rules for Early Stage Pipeline Drugs
- 10.4 Narcotic Pain Relieving Drug Pipeline, 2013
 - 10.4.1 Acurox (Acura, Pfizer)
 - 10.4.2 Remoxy (Pfizer, Pain Therapeutics, Durect)
 - 10.4.3 BEMA Buprenorphine (BioDelivery Sciences, Endo Pharmaceuticals)
 - 10.4.4 Morphine Glucuronide (Paion)
 - 10.4.5 MoxDuo IR (Shire; China Aoxing; QRxPharma)
 - 10.4.6 Acuracet (Pfizer, Acura)
 - 10.4.7 ARX 02 (AcelRx Pharmaceuticals)
 - 10.4.8 Zohydro ER (Zogenix)
 - 10.4.9 COL-003 (Collegium)
 - 10.4.10 ALO 02 (Pfizer)
 - 10.4.11 Subsys (Insys Therapeutics)
 - 10.4.12 Oxceta (Pfizer, Acura)
- 10.5 Non-Narcotic Pain Relieving Drug Pipeline, 2013

- 10.5.1 Exparel (Pacira Pharmaceuticals)
- 10.5.2 Lofexidine HCl (US WorldMeds)
- 10.5.3 Synera (Nuvo Research)
- 10.5.4 Neosaxitoxin (Proteus SA)
- 10.5.5 Adlea (ALRGX-4975) (Anesiva, Johns Hopkins University)
- 10.5.6 OMS 103 HP (Omeros)
- 10.5.7 Tetrodotoxin (WEX, CK Life Sciences)
- 10.5.8 CE 224535 (Pfizer)
- 10.5.9 MK-2295 (Ligand, Merck & Co.)
- 10.6 Neuropathic Pain Relieving Drug Pipeline, 2013
 - 10.6.1 Retigabine (Valeant, GSK)
 - 10.6.2 Perampanel (Eisai)
 - 10.6.3 Serenbotase (Syntaxin, Allergan)
 - 10.6.4 EMA401 (Spinifex)
 - 10.6.5 KRN5500 (Dara Biosciences)
 - 10.6.6 NT-11624 (Neurotune)
 - 10.6.7 ARC-2022 (Arcion)
 - 10.6.8 ARC-4558 (Arcion)
 - 10.6.9 Amiket (EpiCept)
 - 10.6.10 Ralfinamide (Newron)
 - 10.6.11 Eladur (Durect)
 - 10.6.12 AVP-923 (Avanir Pharmaceuticals)
- 10.7 Anti-Migraine Drug Pipeline, 2013
 - 10.7.1 Zelrix (NuPathe)
 - 10.7.2 BMS-927711 (Bristol-Myers Squibb)
 - 10.7.3 Lasmiditan (CoLucid Pharmaceuticals)
 - 10.7.4 Telcagepant (Merck & Co.)
 - 10.7.5 NXN-188 (NeurAxon)
 - 10.7.6 BGG492 (Novartis)
 - 10.7.7 LY2300559 (Eli Lilly)
- 10.8 Anti-Arthritic Pain Drug Pipeline, 2013
 - 10.8.1 Duexa (Horizon Pharma)
 - 10.8.2 Zavryl/Ibuprofen-PC (PLx Pharma)
 - 10.8.3 Naproxcinod (NicOx)
 - 10.8.4 Lodotra/RAYOS Horizon Pharma, SkyePharma)
 - 10.8.5 Tofacitinib (Pfizer)
 - 10.8.6 Ofatumumab (Genmab, GSK)
 - 10.8.7 Mastinitib (AB Science)
 - 10.8.8 Belimumab (GSK, Human Genome Sciences)

10.9 The Future of Pain Research

10.9.1 Advanced Drug Delivery

10.9.1.1 Delivery of Low Solubility Drugs

10.9.2 Challenges Faced by Novel Painkillers - Monoclonal Antibodies (MAbs)

10.9.3 Novel Opioid Molecules

10.10 Cannabinoids and Pain

11. DRIVERS AND RESTRAINTS IN THE WORLDWIDE PAIN RELIEVING DRUG MARKET, 2013-2023

11.1 STEP/SWOT Analysis of the World Pain Relieving Drug Market, 2013-2023

11.2 Social, Technological, Economic and Political Factors Affecting the Pain Relieving Drug Market (STEP Analysis), 2013-2023

11.2.1 Social Factors Influencing the Pain Relieving Drug Market

11.2.2 Technological Factors Influencing the Pain Relieving Drug Market

11.2.3 Economic Factors Influencing the Pain Relieving Drug Market

11.2.4 Political Factors Influencing the Pain Relieving Drug Market

11.3 Market Drivers

11.4 Market Restraints

11.5 The Pain Market after the Withdrawal of COX-2 Inhibitors

11.6 Lack of Adequate Reimbursement Limits Potential of Pain Drugs

11.7 Reformulations of Existing Drugs Will Drive Market Growth

11.8 Narcotics Market Will Continue to Grow Despite Reported Concerns of Side Effects

11.9 Risk of Intestinal Bleeding Associated With Use of NSAIDs

11.10 Ageing Population

11.11 Patent Expiries Will Lead to Generic Competition

11.12 OTC Switching

11.13 Education in Pain Management is a Key Unmet Need

11.13.1 Personalised Pain Management Therapy

12. RESEARCH INTERVIEWS FROM OUR SURVEY

12.1 Interview with Dr Bradley S. Galer, MD, President of Pain Group, Nuvo Research Inc.

12.1.1 Perspective on the Pain Treatment Market

12.1.2 Challenges in the Pain Treatment Market

12.1.3 Insight on the Topical Pain Relief Market

12.1.4 Thoughts on Arthritic Pain Market Developments

- 12.1.5 Thoughts on Key Submarkets
- 12.1.6 Views on Drivers and Threats
- 12.1.7 Treatments in the R&D Pipeline
- 12.1.8 Future of World Pain Treatment Market
- 12.2 Interview with Dr John Andrews, President and Chief Scientific Officer, NeurAxon.
 - 12.2.1 Perspective on the Pain Treatment Market
 - 12.2.2 Key Unmet Needs
 - 12.2.3 Thoughts on Key Submarkets
 - 12.2.4 Development of the Anti-Migraine Drug Market
 - 12.2.5 Views on Drivers and Threats
 - 12.2.6 Thoughts on National Market Opportunities
 - 12.2.7 Treatments in the R&D Pipeline
 - 12.2.8 Views on the Future of the Market
- 12.3 Interview with Dr Tuulikki Sokka, MD, PhD, Head of Rheumatology, Jyväskylä Central Hospital, Finland.
 - 12.3.1 On Current and Future Anti-arthritic Treatments
 - 12.3.2 On Unmet Needs in the Anti-arthritic Sector
 - 12.3.3 On the R&D Pipeline for Rheumatoid Arthritis
 - 12.3.4 On Drivers of the Anti-arthritic Therapy Sector
 - 12.3.5 On Global Prevalence of Rheumatoid Arthritis

13. CONCLUSIONS

- 13.1 The Pain Drug Market Will Achieve Revenue Growth from 2013
- 13.2 Narcotics Submarket Will Grow Despite Reported Concerns
- 13.3 Strong Growth Expected in Neuropathic and Cancer Pain Submarkets
- 13.4 Botox Approval Expected to Boost Anti-Migraine Submarket
- 13.5 The Anti-Arthritic Pain Drug Submarket Will Remain Strong
- 13.6 Leading National Markets Will Achieve Revenue Growth
- 13.7 The Worldwide Pain Drug Treatment Market Holds Strong Potential from 2013 to 2023

List Of Tables

LIST OF TABLES

Table 2.1 Defining Acute and Chronic Pain

Table 3.1 World Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 3.2 World Pain Relieving Drug Sales Forecasts (\$m), AGRs (%), CAGRs (%) for Submarkets, 2012-2017

Table 3.3 World Pain Relieving Drug Sales Forecasts (\$m), AGRs (%), CAGRs (%) for Submarkets, 2018-2023

Table 3.4 World Pain Relieving Drug Market: Market Shares (%) by Submarkets in 2012, 2017 & 2023

Table 4.1 World Narcotic Pain Relieving Drugs Market: Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.2 Leading Narcotic Pain Relieving Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2012-2017

Table 4.3 Leading Narcotic Pain Relieving Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2018-2023

Table 4.4 World Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 4.5 World Oxycontin ER Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.6 World Opana ER Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.7 World Duragesic Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.8 World Ultram ER Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.9 World Zaldiar/Ixprim Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 4.10 World Other Narcotic Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 5.1 World Non-Narcotic Pain Relieving Drugs Market: Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 5.2 Leading Non-Narcotic Pain Relieving Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2012-2017

Table 5.3 Leading Non-Narcotic Pain Relieving Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2018-2023

Table 5.4 World Non-Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 5.5 Advil North American Formulations, 2013

Table 5.6 World Advil Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 5.7 Panadol Formulations, 2013

- Table 5.8 World Panadol Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 5.9 World Bayer Aspirin Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 5.10 World Efferalgan Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 5.11 Tylenol Products, 2013
- Table 5.12 World Tylenol Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 5.13 World Other Non-Narcotic Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.1 Key Drugs Indicated for Neuropathic Pain, 2013
- Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2013
- Table 6.3 World Neuropathic Pain Relieving Drugs Market: Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.4 Rising Prevalence of Diabetes, 2011, 2030 & 2050
- Table 6.5 Leading Neuropathic Pain Relieving Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.6 World Neuropathic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023
- Table 6.7 World Lyrica Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.8 World Cymbalta Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.9 World Lidoderm Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.10 World Neurontin Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 6.11 World Nucynta Franchise Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.1 World Anti-Migraine Drugs Market: Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.2 Leading Anti-Migraine Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.3 World Anti-Migraine Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023
- Table 7.4 World Maxalt Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.5 World Zomig Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.6 World Relpax Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.7 World Imitrex/Imigran Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.8 World Botox Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.9 World Axert Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 7.10 World Treximet Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023
- Table 8.1 Examples of Anti-Arthritic Pain Drugs, 2013
- Table 8.2 World Anti-Arthritic Drugs Market: Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.3 World Anti-Arthritic Drugs Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 8.4 Leading Anti-Arthritic Drugs: Sales Forecasts (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.5 World Humira Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.6 World Enbrel Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.7 World Remicade Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.8 World Rituxan Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.9 World Celebrex Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.10 World Voltaren Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 8.11 World Arcoxia Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.1 Pain Relieving Drug Sales Forecasts (\$m), AGRs (%), CAGRs (%) for Leading National Markets, 2012-2017

Table 9.2 Pain Relieving Drug Sales Forecasts (\$m), AGRs (%), CAGRs (%) for Leading National Markets, 2018-2023

Table 9.3 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2012, 2017 & 2023

Table 9.4 US: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.5 Japan: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.6 Germany: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.7 France: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.8 UK: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGR (%), 2012-2023

Table 9.9 Italy: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.10 Spain: Pain Relieving Drugs Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.11 China: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.12 Brazil: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.13 Russia: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.14 India: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.15 Turkey: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 9.16 Rest of the World: Pain Relieving Drug Sales Forecast (\$m), AGRs (%), CAGRs (%), 2012-2023

Table 10.1 R&D Pipeline for Narcotic Pain Drugs, 2013

Table 10.2 R&D Pipeline for Non-Narcotic Pain Drugs, 2013

Table 10.3 R&D Pipeline for Neuropathic Pain Drugs, 2013

Table 10.4 R&D Pipeline for Anti-Migraine Pain Drugs, 2013

Table 10.5 R&D Pipeline for Anti-Arthritic Pain Drugs, 2013

Table 11.1 STEP Analysis of the Pain Relieving Drug Market, 2013-2023

Table 11.2 SWOT Analysis of the Pain Relieving Drug Market, 2013-2023

Table 11.3 World Population Forecast, 2012-2023

About

Botox (Allergan): Market Analysis and Forecast, 2013-2023

Botox (onabotulinumtoxinA) is a protein and neurotoxin produced by the bacterium *Clostridium botulinum*. Botox is manufactured by Allergan Inc., and is used for cosmetic and therapeutic purposes. Therapeutic uses include the treatment of certain neuromuscular disorders, hyperhidrosis, prophylactic treatment of headaches in adults with chronic migraine and urinary incontinence.

Botox was first approved by the US FDA in 1989 for the treatment of two eye muscle disorders, strabismus and blepharospasm, making it the first botulinum toxin type A product approved in the world. Since its first approval, Botox has been approved by regulatory authorities worldwide as a treatment for approximately 25 unique indications in approximately 85 countries. Botox was first approved for certain aesthetic uses in 2002.

Since the FDA's approval of Dysport, a competing product, the FDA has required that all botulinum toxins marketed in the US include a boxed warning regarding the symptoms associated with the spread of botulinum toxin beyond the injection site along with a corresponding risk evaluation and mitigation strategies (REMS). However, apparently there has not been a confirmed case of spread of toxin effect when Botox has been used at the recommended dose to treat chronic migraine, reports also indicate.

Botox Will Boost World Migraine Sales

In 2012, total global sales of Botox reached \$1,767m, a rise of 13% over the previous year. Therapeutic sales accounted for 52% of the total global sales figures in 2012. In October 2010 Botox became a first in class drug when it was approved for prophylaxis of headaches in adults with chronic migraine. Botox is now approved for the prophylactic treatment of adult chronic migraine in approximately 25 countries, including the UK and almost all other countries in the European Union as well as Australia, Brazil, Canada, India and Korea. Visiongain estimates that chronic migraine treatment with Botox generated \$260m sales in 2012. In May 2012 Allergan announced that the National Institute for Health and Clinical Excellence (NICE) is recommending Botox for the prophylaxis (prevention) of headache in adults with chronic migraine, highlighting the confidence that Botox treatment has generated since FDA approval in 2010.

Visiongain's Botox sales forecast only includes sales attributed to migraine treatment. Visiongain believes that Botox sales for migraine will increase steadily through the entire forecast period. Generic competition is not expected in the first half of the forecast period, as Botox is a biologic drug and the uptake of biosimilar products in the US is expected to be slow. Visiongain believes that the launch of Botox as a chronic migraine treatment has promoted awareness of new treatment options among people having migraines, therefore helping to drive the overall growth of the anti-migraine market as undiagnosed patients demand treatments. Visiongain believes that migraine revenues for Botox will rise steadily over the first half of the forecast period, reaching \$425m by 2017, representing a CAGR of 10.4% for the forecast period 2012-2017. Sales will continue to grow at a slower rate towards the end of the forecast period, owing to competition from other biologics being introduced to the market. By 2023 sales will reach \$533m, representing a CAGR of 6.8% for the entire forecast period 2012-2023.

I would like to order

Product name: World Pain Relieving Drug Market 2013-2023

Product link: <https://marketpublishers.com/r/W5C0C508213EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W5C0C508213EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970